Godavari Drugs Stock Falls to 52-Week Low of Rs.75.45

Stock Performance and Market Context

On 25 Nov 2025, Godavari Drugs opened the trading session with a gap down of 3.84%, reflecting immediate selling pressure. Throughout the day, the stock's price declined further, hitting an intraday low of Rs.75.45, representing a 7.22% drop from the previous close. This performance underperformed the Pharmaceuticals & Biotechnology sector by 5.44% on the same day.

Currently, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downward trend. This contrasts with the broader market, where the Sensex, despite closing slightly lower by 0.04% at 84,866.90, remains close to its 52-week high of 85,801.70 and is trading above its 50-day and 200-day moving averages.

Long-Term Price Movement

Over the past year, Godavari Drugs has recorded a price decline of 34.06%, a stark contrast to the Sensex's 5.92% gain during the same period. The stock's 52-week high was Rs.133.90, indicating a substantial reduction in market value over the last twelve months. This underperformance extends beyond the last year, with the stock also lagging behind the BSE500 index over the past three years and the recent three-month period.

Financial Metrics and Business Performance

Godavari Drugs' financial data over recent periods highlights several areas of concern. The company’s net sales for the nine months ended have shown a contraction of 21.64%, amounting to Rs.75.96 crores. Profit after tax (PAT) for the same period stands at Rs.2.93 crores, reflecting a decline of 45.83%. Operating cash flow for the year is reported at Rs.11.20 crores, which is among the lowest levels recorded.

Over the last five years, the compound annual growth rate (CAGR) for net sales has been negative at 0.27%, indicating limited expansion in revenue generation. The company’s ability to service its debt is constrained, with a Debt to EBITDA ratio of 3.27 times, suggesting elevated leverage relative to earnings before interest, tax, depreciation, and amortisation.

Valuation and Return Metrics

Despite the challenges, Godavari Drugs exhibits a return on capital employed (ROCE) of 9.1%, which is considered attractive within its sector. The enterprise value to capital employed ratio stands at 1.2, indicating that the stock is trading at a discount compared to historical valuations of its peers. However, the stock’s profitability has declined by 44.5% over the past year, aligning with the downward trend in share price.

Shareholding and Sector Position

The majority ownership of Godavari Drugs remains with its promoters. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance in recent sessions. While small-cap stocks in the broader market have shown gains, Godavari Drugs has not mirrored this trend, continuing to face headwinds.

Summary of Recent Trends

Godavari Drugs’ recent price movement to a 52-week low of Rs.75.45 reflects a continuation of a multi-year decline in market valuation. The stock’s performance contrasts with broader market indices and sectoral averages, which have maintained relative strength. Financial indicators point to subdued revenue growth, declining profitability, and elevated leverage, factors that have contributed to the current market assessment.

While the stock is trading at a valuation discount relative to peers, the recent financial results and price action underscore the challenges faced by the company in maintaining growth and earnings momentum.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →